Price Chart

Profile

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
URL https://www.mannkindcorp.com
Investor Relations URL https://investors.mannkindcorp.com
HQ State/Province Connecticut
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Feb. 27, 2024
Last Earnings Release Nov. 07, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
URL https://www.mannkindcorp.com
Investor Relations URL https://investors.mannkindcorp.com
HQ State/Province Connecticut
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Feb. 27, 2024
Last Earnings Release Nov. 07, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A